6-K

NewAmsterdam Pharma Company N.V.

August 14, 2023

/s/ Michael Davidson

Name: Michael Davidson

Title: Chief Executive Officer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2023

Commission File Number: 001-41562

NewAmsterdam Pharma Company N.V.

(Exact name of registrant as specified in its charter)

Gooimeer 2-35

1411 DC Naarden

The Netherlands

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On August 14, 2023, the Company issued a press release announcing it has appointed William “BJ” Jones as Chief Commercial Officer. A copy of the press release is furnished as Exhibit 99.1 to this Report on Form 6-K.

On August 14, 2023, NewAmsterdam Pharma Company N.V. (the “Company”) posted an updated corporate investor presentation on its website (https://www.newamsterdampharma.com/). A copy of the corporate investor presentation is furnished as Exhibit 99.2 to this Report on Form 6-K. The information contained on, or that can be accessed from, the Company’s website is not incorporated into, and does not constitute a part of, this Report on Form 6-K.

EXHIBIT INDEX


Exhibit No.		Description

99.1		Press Release, dated August 14, 2023.

99.2		NewAmsterdam Pharma Company N.V. Corporate Presentation

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.